Dr. Reddy's Laboratories · Analyst questions, management answers, and the quality of the response where the ledger is available.
ConCallIQ research layer
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Questions audited
12
Answered directly
79%
Numeric claims
3
Consistency
contradicted
Question ledger
Kunal Damesha · Macquarie Capital
directThe reason the free cash flow is a bit on the lower side is because of fluctuation in factoring. You know, we do the factoring in various markets, largely in the US, depending on the interest rates and the benefit we get, and because of that, we have rolled back factoring a little bit in this quarter.
Kunal Damesha · Macquarie Capital
directThere are also some one-offs, like increase in freight rates because of some route issues and the Red Sea. Also a few one-offs in farm. Overall, we are confident that our SG&A percentage is going to be within the range of 27%-28% for the full year.
Kunal Damesha · Macquarie Capital
partialSo the answer to the first part, yes, we are on track. How many exact first to file, anybody knows? I don't know exactly to tell you, Kunal. We'll come back to you.
Neha Manpuria · Bank of America
partialThe Northstar, the new acquisitions, once come, will be somewhere around the $300 million. So altogether it's $600 million dollar plus, growing. Likely that we want to build on the platform of Northstar and to add more assets in the future. So, we see it as obviously a business that we speak in billions in the future.
Neha Manpuria · Bank of America
directDenosumab is next year, and what are the other products that you are selling? Abatacept should be December 26th, hopefully, and depends on the approvals or marks beginning of 27th, the calendar.
Amey Chalke · JM Financial
directSo most of it is from the base business. Most of it is the products that we had before, and the contribution of the three products helped the growth, but the lion's share of the growth came from products that we had before.
Amey Chalke · JM Financial
directYeah. So it's, let's say without the vaccine, it's probably mid-single digits, without it.
Damayanti Kerai · HSBC
partialOn biologics, we have just maybe just to frame what we call biologics in the company. We have biosimilars, which is about, I think, if I'm not mistaken, 20%? No, of the R&D. About 20% of the R&D and about 10% of the profit.
Surya Patra · PhilipCapital India Private Limited
partialThat specific investment is for the CDMO activity of the biologics for Aurigene. So that's the primary purpose of this. The level of investment is a few hundred INR crores. I don't remember exactly how much.
Shyam Srinivasan · Goldman Sachs
directFirst, we believe that we have about $2.5 billion that we can invest in organically. The primary way to use it is less of mergers and acquisitions, and more about collaborations, licensing, and from time to time, we will buy also assets or rights to the assets.
Shyam Srinivasan · Goldman Sachs
directWe are looking at all the deals in India. If the deal is better than across the capital, absolutely, we'll do it, and India will be absolutely a priority.
Kunal Damesha · Macquarie Capital
partialWe are still investing in our Bachupally facility. The intent is to become something like 60 kiloliter in that facility. This probably will take us additional two years to reach that level. I think 15, if I remember, 15,000.
